Patents Assigned to Tolmar Therapeutics, Inc.
-
Patent number: 11147880Abstract: A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.Type: GrantFiled: January 8, 2019Date of Patent: October 19, 2021Assignee: Tolmar Therapeutics, Inc.Inventors: Eric Dadey, John Middleton, Richard L. Norton
-
Patent number: 10794632Abstract: A cover plate for use in lyophilization processes is provided. The cover plate includes a base portion and a plurality of protuberances which project from the base portion. The protuberances are adapted to fit in one or more delivery containers, such as syringe barrels. The cover plate permits the escape of vapor from the one or more delivery containers during a lyophilization process. In addition, the cover plate prevents the escape of lyophilizate from the one or more delivery containers during a lyophilization process. Vent features provided to provide enhanced and preferred venting operations during lyophilization processes.Type: GrantFiled: February 3, 2017Date of Patent: October 6, 2020Assignee: TOLMAR THERAPEUTICS, INC.Inventors: Kevin Stuart McCann, Herbert Robert Brinkman, John Milton Downing
-
Patent number: 10744268Abstract: A plunger rod system for syringes is provided. The system comprises at least one plunger and an associated rod for imparting force to the plunger. The rod comprises an end with a threaded member, and the threaded member comprises threads of a certain geometry that enable ease of installation of the rod within the plunger while also providing resistance to pull-out forces such as may be imparted when pulling or extracting the rod or plunger from a barrel.Type: GrantFiled: December 4, 2015Date of Patent: August 18, 2020Assignee: TOLMAR THERAPEUTICS, INC.Inventors: Kevin McCann, Eric Mugoye, Dominic Madril
-
Patent number: 10206970Abstract: A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.Type: GrantFiled: April 10, 2018Date of Patent: February 19, 2019Assignee: Tolmar Therapeutics, Inc.Inventors: Eric Dadey, John Middleton, Richard L. Norton
-
Patent number: 10047193Abstract: A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit. The polymer is for use in a controlled release formulation for a medicament, preferably leuprolide acetate. The controlled release formulation is administered to a patient as a subcutaneous depot of a flowable composition comprising the polymer, a biocompatible solvent, and the medicament. Controlled release formulations comprising the polymer release leuprolide for treatment of prostate cancer patients over periods of 3-6 months.Type: GrantFiled: December 22, 2017Date of Patent: August 14, 2018Assignee: Tolmar Therapeutics, Inc.Inventor: Richard L. Dunn
-
Patent number: 9974824Abstract: A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.Type: GrantFiled: April 18, 2017Date of Patent: May 22, 2018Assignee: Tolmar Therapeutics, Inc.Inventors: Eric Dadey, John Middleton, Richard L. Norton
-
Patent number: 9914802Abstract: A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit. The polymer is for use in a controlled release formulation for a medicament, preferably leuprolide acetate. The controlled release formulation is administered to a patient as a subcutaneous depot of a flowable composition comprising the polymer, a biocompatible solvent, and the medicament. Controlled release formulations comprising the polymer release leuprolide for treatment of prostate cancer patients over periods of 3-6 months.Type: GrantFiled: September 5, 2017Date of Patent: March 13, 2018Assignee: Tolmar Therapeutics, Inc.Inventor: Richard L. Dunn
-
Patent number: 9655970Abstract: A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.Type: GrantFiled: December 19, 2016Date of Patent: May 23, 2017Assignee: Tolmar Therapeutics, Inc.Inventors: Eric Dadey, John Middleton, Richard L. Norton
-
Patent number: 9561282Abstract: A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.Type: GrantFiled: October 27, 2015Date of Patent: February 7, 2017Assignee: Tolmar Therapeutics, Inc.Inventors: Eric Dadey, John Middleton, Richard L. Norton
-
Patent number: 9539333Abstract: A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit. The polymer is for use in a controlled release formulation for a medicament, preferably leuprolide acetate. The controlled release formulation is administered to a patient as a subcutaneous depot of a flowable composition comprising the polymer, a biocompatible solvent, and the medicament. Controlled release formulations comprising the polymer release leuprolide for treatment of prostate cancer patients over periods of 3-6 months.Type: GrantFiled: February 3, 2016Date of Patent: January 10, 2017Assignee: Tolmar Therapeutics, Inc.Inventor: Richard L. Dunn
-
Patent number: 9308162Abstract: The present invention relates to biocompatible oligomer-polymer compositions for the in situ formation of implants, wherein the implants release a bioactive agent, a metabolite, or a prodrug thereof, at a controlled rate. The sustained release delivery system includes a flowable composition containing a bioactive agent, a metabolite, or a prodrug thereof, and an implant containing a bioactive agent, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, a biocompatible end-capped oligomeric liquid, and a bioactive agent, a metabolite, or a prodrug thereof.Type: GrantFiled: June 3, 2009Date of Patent: April 12, 2016Assignee: Tolmar Therapeutics, Inc.Inventor: Richard L. Norton
-
Patent number: 9283282Abstract: A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit. The polymer is for use in a controlled release formulation for a medicament, preferably leuprolide acetate. The controlled release formulation is administered to a patient as a subcutaneous depot of a flowable composition comprising the polymer, a biocompatible solvent, and the medicament. Controlled release formulations comprising the polymer release leuprolide for treatment of prostate cancer patients over periods of 3-6 months.Type: GrantFiled: August 19, 2014Date of Patent: March 15, 2016Assignee: Tolmar Therapeutics, Inc.Inventor: Richard L. Dunn
-
Patent number: 9254307Abstract: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.Type: GrantFiled: May 20, 2010Date of Patent: February 9, 2016Assignee: Tolmar Therapeutics, Inc.Inventors: Richard L. Dunn, John Steven Garrett, Harish Ravivarapu, Bhagya L. Chandrashekar
-
Patent number: 9187593Abstract: A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.Type: GrantFiled: February 13, 2008Date of Patent: November 17, 2015Assignee: Tolmar Therapeutics, Inc.Inventors: Eric Dadey, John Middleton, Richard L. Norton
-
Patent number: 9003676Abstract: A process for lyophilizing a solution of an active agent in a container is provided. Solution of active agent is deposited into a container, the container is covered with a covering plate and placed inside a lyophilizing apparatus. Lyophilization can be conducted to dryness by radiation, convection or both. Also provided is a device made by this process, an active agent-plastic administration device (e.g., a syringe), containing an active agent in the form of lyophilized cake, and an array of such administration devices.Type: GrantFiled: June 17, 2008Date of Patent: April 14, 2015Assignee: Tolmar Therapeutics, Inc.Inventors: Cody L. Yarborough, Dominic G. Madril, Rajan Bawa
-
Patent number: 8877225Abstract: The present invention provides a constant release copolymer composition adapted for use in a controlled release formulation for a bioactive agent, such as a formulation adapted for implantation within a patient's body tissues as a depot to release the agent over a period of time, wherein the copolymer provides a substantially constant rate of release of the bioactive agent over the time period for which the depot persists in the body tissues. The copolymer includes a PLG copolymer and a PLG oligomer of about 5-10 kDa average molecular weight, which can lack free carboxylic acid groups. When the PLG copolymer is a low burst copolymer, the constant release copolymer composition is a low burst, constant release copolymer composition adapted for implantation in the body tissues of a mammal, wherein a substantially constant rate of release of the bioactive agent is achieved.Type: GrantFiled: June 3, 2009Date of Patent: November 4, 2014Assignee: Tolmar Therapeutics, Inc.Inventors: Richard L. Norton, Eric Dadey
-
Patent number: 8840916Abstract: A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit. The polymer is for use in a controlled release formulation for a medicament, preferably leuprolide acetate. The controlled release formulation is administered to a patient as a subcutaneous depot of a flowable composition comprising the polymer, a biocompatible solvent, and the medicament. Controlled release formulations comprising the polymer release leuprolide for treatment of prostate cancer patients over periods of 3-6 months.Type: GrantFiled: May 22, 2013Date of Patent: September 23, 2014Assignee: Tolmar Therapeutics, Inc.Inventor: Richard L. Dunn
-
Publication number: 20140094484Abstract: The present invention relates to a rapamycin sustained release delivery system for treatment of diseases responsive to rapamycin. The sustained release delivery system of the invention includes a flowable composition containing rapamycin or a rapamycin derivative, which is capable of providing an implant containing the rapamycin or derivative thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid and rapamycin or a rapamycin derivative.Type: ApplicationFiled: October 2, 2012Publication date: April 3, 2014Applicants: QLT Inc., Tolmar Therapeutics, Inc.Inventors: Philippe Maria Clotaire Margaron, Eric Dadey, Christopher M. Lindemann, Ruihong Li
-
Patent number: 8486455Abstract: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.Type: GrantFiled: May 20, 2010Date of Patent: July 16, 2013Assignee: Tolmar Therapeutics, Inc.Inventors: Richard L. Dunn, John Steven Garrett, Harish Ravivarapu, Bhagya L. Chandrashekar
-
Patent number: D908916Type: GrantFiled: June 19, 2018Date of Patent: January 26, 2021Assignee: TOLMAR THERAPEUTICS, INC.Inventors: James Sherman, Joseph Cardon